Posted by Michael Wonder on 20 Dec 2017
Decision to fund cetuximab for head and neck cancer
20 December 2017 - PHARMAC is pleased to announce our decision to fund cetuximab (Erbitux) from 1 February 2018 for the treatment of patients with locally advanced, non-metastatic, squamous cell cancer of the head and neck; subject to certain clinical criteria being met.
This decision was subject to a consultation letter dated 15 November 2017.
The proposal will be implemented as consulted on with the exception of amendment to the Special Authority criteria to allow application by a medical practitioner on the recommendation of a medical oncologist (rather than only by a medical oncologist).
